1060802-09-6

Basic information

• Product Name: 1-(5-Chloro-pyridin-2-yl)-2,2,2-trifluoro-ethanone
• Synonyms: 1-(5-Chloro-pyridin-2-yl)-2,2,2-trifluoro-ethanone
• CAS NO: 1060802-09-6
• Molecular Formula: C7H3ClF3NO
• Molecular Weight: 209.5530296
• Mol File: 1060802-09-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 216.3±35.0 °C(Predicted)
• Appearance: /
• Density: 1.470±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.33±0.10(Predicted)
• CAS DataBase Reference: 1-(5-Chloro-pyridin-2-yl)-2,2,2-trifluoro-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-Chloro-pyridin-2-yl)-2,2,2-trifluoro-ethanone(1060802-09-6)
• EPA Substance Registry System: 1-(5-Chloro-pyridin-2-yl)-2,2,2-trifluoro-ethanone(1060802-09-6)

Safety Data

• Hazardous Substances Data: 1060802-09-6(Hazardous Substances Data)

Usage

General Description

1-(5-Chloro-pyridin-2-yl)-2,2,2-trifluoro-ethanone is a chemical compound with the molecular formula C7H4ClF3NO. It is a yellow crystalline solid that is mainly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The compound is a derivative of pyridine and is characterized by the presence of a chloro group and trifluoroethanone moiety. It is commonly used in organic synthesis and as a building block for the preparation of various functional materials. The chemical properties of 1-(5-Chloro-pyridin-2-yl)-2,2,2-trifluoro-ethanone make it a valuable reagent in the production of diverse pharmaceutical and agrochemical products.

Upstream product

• 31181-89-2 5-chloro-2-pyridine carboxaldehyde 

Relevant articles and documents

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.